The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619267-status-epilepticus-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
- The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
- The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Status Epilepticus
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Status Epilepticus Overview 7
Therapeutics Development 8
Pipeline Products for Status Epilepticus - Overview 8
Pipeline Products for Status Epilepticus - Comparative Analysis 9
Status Epilepticus - Therapeutics under Development by Companies 10
Status Epilepticus - Therapeutics under Investigation by Universities/Institutes 11
Status Epilepticus - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Status Epilepticus - Products under Development by Companies 15
Status Epilepticus - Products under Investigation by Universities/Institutes 16
Status Epilepticus - Companies Involved in Therapeutics Development 17
Marinus Pharmaceuticals, Inc. 17
Sage Therapeutics, Inc. 18
Shire Plc 19
Status Epilepticus - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AMPX-0079 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
fosphenytoin sodium - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ganaxolone - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LSPGR-1 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
midazolam hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
SAGE-217 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
SAGE-689 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Access Report @ https://www.wiseguyreports.com/reports/619267-status-epilepticus-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment